Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762477257P | 2017-03-27 | 2017-03-27 | |
PCT/US2018/024316WO2018183182A1 (en) | 2017-03-27 | 2018-03-26 | Methods and compositions for reduction of immunogenicity |
Publication Number | Publication Date |
---|---|
SG11201908678XAtrue SG11201908678XA (en) | 2019-10-30 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908678XSG11201908678XA (en) | 2017-03-27 | 2018-03-26 | Methods and compositions for reduction of immunogenicity |
Country | Link |
---|---|
US (2) | US20200330590A1 (en) |
EP (1) | EP3601351A1 (en) |
JP (2) | JP7237848B2 (en) |
KR (1) | KR20190133198A (en) |
CN (1) | CN110612309A (en) |
AU (1) | AU2018244276A1 (en) |
BR (1) | BR112019020185A2 (en) |
CA (1) | CA3057841A1 (en) |
CL (1) | CL2019002716A1 (en) |
CO (1) | CO2019011640A2 (en) |
EA (1) | EA201992278A1 (en) |
IL (1) | IL269590A (en) |
MX (1) | MX2019011624A (en) |
SG (1) | SG11201908678XA (en) |
WO (1) | WO2018183182A1 (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
KR20170110601A (en) | 2015-02-05 | 2017-10-11 | 몰레큘러 템플레이츠, 인코퍼레이션. | Multivalent CD20 binding molecules comprising a < RTI ID = 0.0 > cigarotoxin A < / RTI > |
IL268443B2 (en) | 2018-04-17 | 2024-07-01 | Molecular Templates Inc | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
TW202104260A (en)* | 2019-04-05 | 2021-02-01 | 美商西建公司 | Engineering of an antibody for tumor-selective binding of cd47 |
CN114206912B (en) | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | Methods and reagents for reducing interference from drugs that bind CD47 in serological assays |
CN114599392A (en)* | 2019-10-31 | 2022-06-07 | 四十七公司 | anti-CD 47 and anti-CD 20 based treatment of leukemia |
AU2021205144A1 (en)* | 2020-01-09 | 2022-08-25 | Innovent Biologics (Suzhou) Co., Ltd. | Application of combination of anti-CD47 antibody and anti-CD20 antibody in preparation of drugs for preventing or treating tumors |
EP4225793A1 (en) | 2020-10-07 | 2023-08-16 | Celgene Corporation | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (en) | 1990-04-17 | 1994-11-18 | Eurand Int | METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK0672142T3 (en) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalent and multi-specific binding proteins as well as their preparation and use |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
DE69427974T2 (en) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | PRODUCTION OF ANTIBODIES OR FUNCTIONAL PARTS THEREOF, DERIVED FROM HEAVY CHAINS OF IMMUNOGLOBULINES FROM CAMELIDAE |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
BR9606706A (en) | 1995-10-16 | 1999-04-06 | Unilever Nv | Bispecific or bivalent antibody fragment analog use process to produce the same |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
CA2266629C (en) | 1996-10-01 | 2002-04-16 | Cima Labs Inc. | Taste-masked microcapsule compositions and methods of manufacture |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
DE60042789D1 (en) | 1999-11-29 | 2009-10-01 | Bac Ip B V | IMMOBILIZED ANTIGEN-BINDING MOLECULES FROM A DOMAIN |
IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
US20050042664A1 (en) | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
EP2111869A1 (en)* | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
US20140140989A1 (en)* | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
CN104583235B (en) | 2012-06-08 | 2019-03-01 | 苏特罗生物制药公司 | The antibody of the Unnatural amino acid residues containing site-specific, its preparation and application |
HUE045227T2 (en) | 2012-08-31 | 2019-12-30 | Sutro Biopharma Inc | Modified amino acids containing an azido group |
CA2894439A1 (en)* | 2012-12-12 | 2014-06-19 | Vasculox Inc. | Therapeutic cd47 antibodies |
EP4137518A1 (en)* | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
US20170002060A1 (en)* | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
US10870699B2 (en) | 2014-12-30 | 2020-12-22 | Celgene Corporation | Anti-CD47 antibodies and uses thereof |
JP2018535692A (en)* | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターErasmus University Medical Center | Anti-CD47 antibody and method of use |
Publication number | Publication date |
---|---|
CN110612309A (en) | 2019-12-24 |
JP7237848B2 (en) | 2023-03-13 |
US20240075133A1 (en) | 2024-03-07 |
CL2019002716A1 (en) | 2020-05-29 |
EP3601351A1 (en) | 2020-02-05 |
IL269590A (en) | 2019-11-28 |
JP2020515577A (en) | 2020-05-28 |
WO2018183182A8 (en) | 2019-11-14 |
CO2019011640A2 (en) | 2020-02-18 |
WO2018183182A1 (en) | 2018-10-04 |
BR112019020185A2 (en) | 2020-06-02 |
MX2019011624A (en) | 2019-12-05 |
JP2023052145A (en) | 2023-04-11 |
AU2018244276A1 (en) | 2019-10-17 |
EA201992278A1 (en) | 2020-03-03 |
CA3057841A1 (en) | 2018-10-04 |
KR20190133198A (en) | 2019-12-02 |
US20200330590A1 (en) | 2020-10-22 |
Publication | Publication Date | Title |
---|---|---|
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility |